cheaptrix/billsum-US_congress_and_house huggingface dataset:
To remove from the John H. Chafee Coastal Barrier Resources System certain properties in North Carolina.

To remove from the John H. Chafee Coastal Barrier Resources System certain properties in North Carolina. 1. Removal of properties in North Carolina from John H. Chafee Coastal Barrier Resources System (a) In general The Secretary of the Interior shall revise one or more maps included in the set of maps entitled Coastal Barrier Resources System 16 U.S.C. 3503(a) (1) Lot Number 3, Waters Edge in Hampstead, NC 28443. (2) 182 S Beach Road, Wilmington, NC 28405. (3) 311 Windchase Lane, Wilmington, NC 28409. (4) 225 Chimney Lane Wilmington, NC 28411. (b) Availability The Secretary of the Interior shall keep each map revised under subsection (a) on file and available for inspection in accordance with section 4(b) of the Coastal Barrier Resources Act ( 16 U.S.C. 3503(b)

Summary: Directs the Secretary of the Interior to revise the Coastal Barrier Resources System maps relating to the John H. Chafee Coastal Barrier Resources System units in North Carolina to remove the following properties from such system: Lot Number 3, Waters Edge in Hampstead, NC 28443; 182 S Beach Road, Wilmington, NC 28405; 311 Windchase Lane, Wilmington, NC 28409; and 225 Chimney Lane Wilmington, NC 28411.
Basel III CASE Act

To require the Board of Governors of the Federal Reserve System, the Federal Deposit Insurance Corporation, and the Office of the Comptroller of the Currency to conduct an empirical impact study on proposed rules relating to the International Basel III agreement on general risk-based capital requirements, as they apply to smaller financial institutions. 1. Short title This Act may be cited as the Basel III Commonsense Approach for Small Entities Act Basel III CASE Act 2. Final rules pending Impact Study (a) In general The Board of Governors of the Federal Reserve System, the Federal Deposit Insurance Corporation, and the Office of the Comptroller of the Currency (in this Act collectively referred to as the Federal banking agencies (b) Issues To be studied The study required by this section shall include— (1) a quantitative analysis of the impact of such rule on the financial services sector of the United States, specifically community, mid-size, and regional financial institutions; and (2) a determination of the long-term impact of such rule, including changes to the current risk weight framework. 3. Voluntary Participation Any financial institution may voluntarily provide information for the study upon the request of the Federal banking agencies, but may not be required to provide such information. 4. Final report (a) Availability to the public A final report on the completed study required by this Act shall be made available to the public for notice and comment for a period of not less than 3 months. (b) Review The Federal banking agencies shall review any comments submitted under subsection (a), and following such review, shall prescribe new rules, if appropriate, based on the results of the study and such comments. Notwithstanding any other provision of law, a new rulemaking following such comment period shall include an additional comment period of not less than 3 months.

Summary: Basel III Commonsense Approach for Small Entities Act or Basel III CASE Act - Directs the Board of Governors of the Federal Reserve System, the Federal Deposit Insurance Corporation (FDIC), and the Office of the Comptroller of the Currency, before issuing any final rule in relation to proposals they have issued for the International Basel III agreement on general risk-based capital requirements, to conduct an empirical study that includes: (1) a quantitative analysis of the rule's impact on the U.S. financial services sector, specifically community, mid-size, and regional financial institutions; and (2) a determination of the long-term impact of the rule, including changes to the current risk weight framework. Permits a financial institution to provide information voluntarily for the study upon agency request, but prohibits agencies from requiring such information. Requires the study to be made available to the public for notice and comment.
Petroleum Coke Transparency and Public Health Study Act

To require the Secretary of Health and Human Services, in consultation with the Administrator of the Environmental Protection Agency, to conduct a study on the public health and environmental impacts of the production, transportation, storage, and use of petroleum coke, and for other purposes. 1. Short title This Act may be cited as the Petroleum Coke Transparency and Public Health Study Act 2. Findings Congress finds the following: (1) In Detroit, piles of petroleum coke have been stored in the open air on the banks of the Detroit River. (2) Domestic production of petroleum coke is expected to increase if the Keystone XL pipeline is constructed. (3) State regulators, communities, and industry stakeholders would benefit from a complete understanding of petroleum coke and the potential impact on public health related to the production, transportation, storage, and use of petroleum coke. 3. Study of petroleum coke public health and environmental impacts Not later than 90 days after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with the Administrator of the Environmental Protection Agency, shall transmit to Congress the results of a study regarding the public health and environmental impacts of the production, transportation, storage, and use of petroleum coke. 4. Consolidation of petroleum coke research Not later than 120 days after the date of enactment of this Act, the Secretary of Health and Human Services shall compile and publish on a publicly available website the results of all federally conducted research related to the public health and environmental impacts of the production, transportation, storage, and use of petroleum coke.

Summary: Petroleum Coke Transparency and Public Health Study Act - Requires the Secretary of Health and Human Services (HHS) to transmit to Congress, within 90 days after enactment of this Act, the results of a study regarding the public health and environmental impacts of the production, transportation, storage, and use of petroleum coke. Requires the Secretary to compile and make publicly available the results of all federally conducted research related to such impacts.
To prevent the Secretary of the Treasury from expanding United States bank reporting requirements with respect to interest on deposits paid to nonresident aliens.

To prevent the Secretary of the Treasury from expanding United States bank reporting requirements with respect to interest on deposits paid to nonresident aliens. 1. Prohibition on Treasury Regulations with respect to information reporting on certain interest paid to nonresident aliens Except to the extent provided in Treasury Regulations as in effect on February 21, 2011, the Secretary of the Treasury shall not require (by regulation or otherwise) that an information return be made by a payor of interest in the case of interest— (1) which is described in section 871(i)(2)(A) (2) which is paid— (A) to a nonresident alien, and (B) on a deposit maintained at an office within the United States.

Summary: Prohibits the Secretary of the Treasury from requiring a payor of interest to file an information return on interest that is not effectively connected with a trade or business within the United States and that is paid to a nonresident alien on a deposit maintained at an office within the United States.
Sanctity of Human Life Act

To provide that human life shall be deemed to begin with fertilization. 1. Short title This Act may be cited as the Sanctity of Human Life Act 2. Declaration In the exercise of the powers of the Congress, including Congress’ power under article I, section 8 of the Constitution, to make necessary and proper laws, and Congress’ power under section 5 of the 14th article of amendment to the Constitution of the United States— (1) the Congress declares that— (A) the right to life guaranteed by the Constitution is vested in each human being, and is the paramount and most fundamental right of a person; and (B) the life of each human being begins with fertilization, cloning, or its functional equivalent, irrespective of sex, health, function or disability, defect, stage of biological development, or condition of dependency, at which time every human being shall have all the legal and constitutional attributes and privileges of personhood; and (2) the Congress affirms that the Congress, each State, the District of Columbia, and all United States territories have the authority to protect the lives of all human beings residing in its respective jurisdictions. 3. Definitions For purposes of this Act: (1) Fertilization The term fertilization (2) Cloning The term cloning (3) Human; human being The terms human human being

Summary: Sanctity of Human Life Act - Declares that: (1) the right to life guaranteed by the Constitution is vested in each human and is the person's paramount and most fundamental right; (2) each human life begins with fertilization, cloning, or its functional equivalent, at which time every human has all legal and constitutional attributes and privileges of personhood; and (3) Congress, each state, the District of Columbia, and all U.S. territories have the authority to protect all human lives.
Clinical Trial Cancer Mission 2020 Act

To amend the Public Health Service Act to enhance the clinical trial registry data bank reporting requirements and enforcement measures. 1. Short title This Act may be cited as the Clinical Trial Cancer Mission 2020 Act 2. Enhancing clinical trial registry data bank reporting requirements and enforcement measures (a) Clarification that clinical trial registry data bank requirements apply regardless of trial outcomes Section 402(j)(1)(A)(i) of the Public Health Service Act ( 42 U.S.C. 282(j)(1)(A)(i) , whether or not such a clinical trial results in a positive or negative outcome (b) Application to grants from Department of Defense Section 402(j)(5)(A)(i) of such Act ( 42 U.S.C. 282(j)(5)(A)(i) the Department of Defense or agency of (c) Enhanced enforcement Section 402(j)(5)(A) of such Act ( 42 U.S.C. 282(j)(5)(A) (v) Enhanced enforcement After the 30-day period described in clause (iii), if the head of an agency referred to in clause (i), as applicable, verifies that a grantee has not submitted clinical trial information as described in clause (ii), with respect to an applicable clinical trial that is funded in whole or in part by a grant from the agency, such grantee— (I) shall not be eligible to receive any remaining funding for the grant or funding for a future Federal grant until such time as the grantee comes into compliance with all applicable reporting requirements under this subsection; and (II) shall be liable to the United States for repayment of any amount provided under the grant for the clinical trial for which the grantee failed to comply with such reporting requirements. .

Summary: Clinical Trial Cancer Mission 2020 Act - Revises clinical trial registry data bank provisions of the Public Health Service Act to: (1) include a device or drug clinical trial whether or not it results in a positive or negative outcome, and (2) subject clinical trials funded by the Department of Defense (DOD) to requirements to certify information submissions to the Director of the National Institutes of Health (NIH). Restricts funding for a grantee and makes the grantee liable to the United States for repayment of any grant amount provided, if the grantee has not submitted clinical trial information within the 30-day correction period for noncompliance.
Save Our Soldiers' Lungs Act

To define the term covered waste 1. Short title This Act may be cited as the Save Our Soldiers’ Lungs Act 2. Clarification of prohibition on disposing of waste in open-air burn pits For the purposes of Department of Defense Instruction 4715.19, issued as required by section 317 of the National Defense Authorization Act for Fiscal Year 2010 ( Public Law 111–84 10 U.S.C. 2701 covered waste (1) Tires. (2) Treated wood. (3) Batteries. (4) Plastics, except insignificant amounts of plastic remaining after a good-faith effort to remove or recover plastic materials from the solid waste stream. (5) Munitions and explosives, the destruction of which is covered in Department of Defense Instruction 6055.09–M (Reference (i)). (6) Compressed gas cylinders, unless empty with valves removed. (7) Fuel containers, unless completely evacuated of its contents. (8) Aerosol cans. (9) Polychlorinated biphenyls. (10) Petroleum, oils, and lubricants products (other than waste fuel for initial combustion). (11) Asbestos. (12) Mercury. (13) Foam tent material. (14) Any item containing any of the materials referred to in a preceding paragraph.

Summary: Save Our Soldiers' Lungs Act - Includes within the definition of "covered waste" for purposes of the Department of Defense (DOD) prohibition against disposal of certain waste in open-air burn pits: tires; treated wood; batteries; plastics, except insignificant amounts of plastic remaining after a good-faith effort to remove or recover plastic materials from the solid waste stream; munitions and explosives; compressed gas cylinders, unless empty with valves removed; fuel containers, unless completely evacuated of contents; aerosol cans; polychlorinated biphenyls; petroleum, oils, and lubricants products (other than waste fuel for initial combustion); asbestos; mercury; foam tent material; and any item containing any of such materials.
For the relief of Amer Numan Adi.

For the relief of Amer Numan Adi. 1. Permanent resident status for Amer Numan Adi (a) In general Notwithstanding subsections (a) and (b) of section 201 of the Immigration and Nationality Act, Amer Numan Adi shall be eligible for issuance of an immigrant visa or for adjustment of status to that of an alien lawfully admitted for permanent residence upon filing an application for issuance of an immigrant visa under section 204 of such Act or for adjustment of status to lawful permanent resident. (b) Adjustment of status If Amer Numan Adi enters the United States before the filing deadline specified in subsection (c), he shall be considered to have entered and remained lawfully and shall, if otherwise eligible, be eligible for adjustment of status under section 245 of the Immigration and Nationality Act as of the date of the enactment of this Act. (c) Deadline for application and payment of fees Subsections (a) and (b) shall apply only if the application for issuance of an immigrant visa or the application for adjustment of status is filed with appropriate fees within 2 years after the date of the enactment of this Act. (d) Reduction of immigrant visa number Upon the granting of an immigrant visa or permanent residence to Amer Numan Adi, the Secretary of State shall instruct the proper officer to reduce by 1, during the current or next following fiscal year, the total number of immigrant visas that are made available to natives of the country of the alien’s birth under section 203(a) of the Immigration and Nationality Act or, if applicable, the total number of immigrant visas that are made available to natives of the country of the alien’s birth under section 202(e) of such Act. (e) Denial of preferential immigration treatment for certain relatives The natural parents, brothers, and sisters of Amer Numan Adi shall not, by virtue of such relationship, be accorded any right, privilege, or status under the Immigration and Nationality Act.

Summary: Provides for the relief of Amer Numan Adi.
Infant Formula Protection Act of 2013

To amend the Federal Food, Drug, and Cosmetic Act to treat infant formula as adulterated if its use-by-date has passed. 1. Short title This Act may be cited as the Infant Formula Protection Act of 2013 2. Expired infant formula (a) Adulteration Section 412 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 350a (1) in paragraph (2), by striking or (2) in paragraph (3), by striking the period at the end and inserting , or (3) by adding at the end the following: (4) such infant formula’s use-by date, as specified in the formula’s labeling in accordance with section 107.20 of title 21, Code of Federal Regulations (or any successor regulations) has passed. . (b) Applicability The amendment made by subsection (a) applies beginning on the date that is 6 months after the date of enactment of this Act.

Summary: Infant Formula Protection Act of 2013 - Amends the Federal Food, Drug, and Cosmetic Act to deem an infant formula, including an infant formula powder, to be adulterated if its use-by date has passed.
Hawaiian Homeownership Opportunity Act of 2013

To reauthorize the programs of the Department of Housing and Urban Development for housing assistance for Native Hawaiians. 1. Short title This Act may be cited as the Hawaiian Homeownership Opportunity Act of 2013 2. Authorization of appropriations for housing assistance Section 824 of the Native American Housing Assistance and Self-Determination Act of 1996 ( 25 U.S.C. 4243 Public Law 106–569 fiscal years fiscal years 2013, 2014, 2015, 2016, and 2017. 3. Loan guarantees for Native Hawaiian housing Section 184A of the Housing and Community Development Act of 1992 ( 12 U.S.C. 1715z–13b Public Law 106–569 (1) Authorization of appropriations In subsection (j)(7), by striking fiscal years fiscal years 2013, 2014, 2015, 2016, and 2017. (2) Authority In subsection (b), by striking or as a result of a lack of access to private financial markets (3) Eligible housing In subsection (c), by striking paragraph (2) and inserting the following new paragraph: (2) Eligible housing The loan will be used to construct, acquire, refinance, or rehabilitate 1- to 4-family dwellings that are standard housing and are located on Hawaiian Home Lands. .

Summary: Hawaiian Homeownership Opportunity Act of 2013 - Amends the Native American Housing Assistance and Self-Determination Act of 1996 and the Housing and Community Development Act of 1992 to extend through FY2017 the authorization of appropriations for housing assistance for Native Hawaiians and loan guarantees for Native Hawaiian housing.
Aged Distilled Spirits Competitiveness Act

To exempt the natural aging process in the determination of the production period for distilled spirits under section 263A 1. Short title This Act may be cited as the Aged Distilled Spirits Competitiveness Act 2. Exemption of natural aging process in determination of production period for distilled spirits under section 263A (a) In general Section 263A(f) (5) Exemption of natural aging process in determination of production period for distilled spirits For purposes of this subsection, the production period for distilled spirits shall be determined without regard to any period allocated to the natural aging process. . (b) Effective date The amendment made by this section shall apply to production periods beginning after the date of the enactment of this Act.

Summary: Aged Distilled Spirits Competitiveness Act - Amends the Internal Revenue Code to exclude from determination of the production period for distilled spirits any period allocated to the natural aging process for purposes of determining whether a taxpayer can expense, rather than capitalize, interest costs paid or incurred during the production period.
To amend the Internal Revenue Code of 1986 to issue regulations covering the practice of enrolled agents before the Internal Revenue Service.

To amend the Internal Revenue Code of 1986 to issue regulations covering the practice of enrolled agents before the Internal Revenue Service. 1. Enrolled agents (a) In general Chapter 77 7529. Enrolled agents (a) In general The Secretary may prescribe such regulations as may be necessary to regulate the conduct of enrolled agents in regards to their practice before the Internal Revenue Service. (b) Use of credentials Any enrolled agents properly licensed to practice as required under rules promulgated under subsection (a) shall be allowed to use the credentials or designation as enrolled agent EA E.A. . (b) Clerical amendment The table of sections for chapter 77 of such Code is amended by adding at the end the following new item: Sec. 7529. Enrolled agents. . (c) Prior regulations Nothing in the amendments made by this section shall be construed to have any effect on part 10 of title 31, Code of Federal Regulations, or any other related Federal rule or regulation issued before the date of the enactment of this Act.

Summary: Amends the Internal Revenue Code to authorize the Secretary of the Treasury to prescribe regulations to regulate the conduct of enrolled agents in their practice before the Internal Revenue Service (IRS). Allows properly licensed enrolled agents to use the credentials or designation as "enrolled agent," "EA," or "E.A."
Preserving Access to Orphan Drugs Act of 2013

To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers. 1. Short title This Act may be cited as the Preserving Access to Orphan Drugs Act of 2013 2. Clarification of orphan drug exception to annual fee on branded prescription pharmaceutical manufacturers and importers (a) In general Paragraph (3) of section 9008(e) of the Patient Protection and Affordable Care Act (Public Law 111–148) is amended to read as follows: (3) Exclusion of orphan drug sales (A) In general The term branded prescription drug sales (i) with respect to which a credit was allowed for any taxable year under section 45C of the Internal Revenue Code of 1986; or (ii) which is approved or licensed by the Food and Drug Administration for marketing solely for one or more rare diseases or conditions. (B) Limitation Subparagraph (A) shall not apply with respect to any drug or biological product after the date on which the drug or biological product is approved or licensed by the Food and Drug Administration for marketing for any indication other than the treatment of a rare disease or condition. (C) Rare disease or condition In this paragraph, the term rare disease or condition . (b) Effective date The amendment made by this section shall take effect as if included in section 9008 of the Patient Protection and Affordable Care Act ( Public Law 111–148

Summary: Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA.